HealthReported
Novartis cholesterol drug setback raises stakes for Amgen, Eli Lilly
Novartis' failure in reducing Lp(a) levels intensifies competition among drugmakers racing to prove lower cholesterol correlates with fewer cardiovascular events.
· 1 min read